Nicusor Iftimia | Precision Medicine | Innovative Research Award | 2701

Published on by Top Pharmaceutical

Innovative Research Award

Nicusor Iftimia
PSI, United States

Research Profile
Affiliation PSI
Country United States
Scopus ID 6603766089
Documents 177
Citations 4,524
h-index 36
Subject Area Precision Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7713-6972

The Innovative Research Award recognizes researchers whose sustained scientific contributions have significantly advanced their respective disciplines through original research, technological innovation, and scholarly impact. Nicusor Iftimia has established a distinguished research profile in precision medicine and biomedical imaging, with extensive publications, a strong citation record, and interdisciplinary contributions that have influenced translational healthcare research.[1] His scholarly work spans optical imaging technologies, diagnostic instrumentation, and clinical applications that support improved patient outcomes.[2]

Abstract

Nicusor Iftimia has developed an internationally recognized research portfolio focused on precision medicine, biomedical optics, and advanced diagnostic technologies. His scientific investigations have supported improvements in optical coherence tomography, image-guided diagnostics, and translational biomedical engineering. The combination of a high publication output, extensive citations, and measurable scholarly influence demonstrates the sustained academic excellence expected for recognition through the Innovative Research Award.[1]

Keywords

Precision Medicine, Optical Coherence Tomography, Biomedical Imaging, Diagnostic Instrumentation, Biomedical Engineering, Clinical Imaging, Medical Devices, Translational Medicine, Optical Diagnostics, Innovative Research.

Introduction

Precision medicine continues to transform healthcare by integrating advanced imaging technologies with patient-specific diagnostic strategies. Researchers working at the intersection of engineering, optics, and medicine contribute substantially to this evolving field through innovations that improve disease detection and clinical decision-making. Nicusor Iftimia has consistently contributed to these developments through multidisciplinary research involving optical technologies and biomedical instrumentation.[2]

Research Profile

Nicusor Iftimia has established a distinguished research profile in precision medicine through extensive contributions to biomedical optics, optical coherence tomography, and advanced medical imaging technologies. His academic portfolio comprises 177 Scopus-indexed publications, more than 4,524 citations, and an h-index of 36, demonstrating sustained scholarly productivity and international research influence. His work emphasizes the development of innovative diagnostic methods and translational biomedical engineering solutions that bridge laboratory research with clinical practice. The breadth of his publications, collaborative research activities, and measurable scientific impact highlight his continued contributions to advancing precision medicine and healthcare technologies.[1][2]

Research Contributions

The research contributions of Nicusor Iftimia emphasize the integration of optical technologies with clinical practice. His publications have supported advances in non-invasive imaging, medical diagnostics, and translational biomedical engineering, enabling more accurate disease assessment and supporting innovation within precision healthcare systems.[3]

Publications

Nicusor Iftimia has authored 177 Scopus-indexed publications covering precision medicine, biomedical optics, optical coherence tomography, medical imaging, and diagnostic instrumentation. His scholarly work has been published in internationally recognized peer-reviewed journals and conference proceedings, demonstrating consistent research productivity and interdisciplinary collaboration. These publications have significantly contributed to the advancement of non-invasive imaging technologies, clinical diagnostics, and translational biomedical engineering. The sustained quality and impact of his research output are reflected by a strong citation record and continued recognition within the global scientific community.[1][2]

Research Impact

The citation metrics and publication record indicate sustained international recognition within biomedical engineering and medical imaging. The research has contributed to technological innovation, interdisciplinary collaboration, and scientific knowledge transfer across academic and healthcare communities.[1]

Award Suitability

Based on measurable scholarly indicators, interdisciplinary research contributions, and international scientific visibility, Nicusor Iftimia demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. His sustained research productivity, technological innovation, and influence within precision medicine provide a strong academic foundation for consideration for the Innovative Research Award.[4]

Conclusion

Nicusor Iftimia’s academic profile reflects long-term excellence in biomedical optics, precision medicine, and diagnostic innovation. His publication history, citation impact, and interdisciplinary research achievements illustrate continued contributions to scientific advancement and demonstrate the qualities recognized through international research excellence awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nicusor Iftimia, Author ID 6603766089. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603766089
  2. Iftimia, N., Yadav, P., Primrose, M., Maguluri, G., Jones, J., Grimble, J., & Sheth, R. A. (2026). AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study. https://doi.org/10.3390/diagnostics16050811
  3. Sampani, K., Mujat, M., Patel, A. H., Kang, C., Iftimia, N., Chatziralli, I., & Sun, J. K. (2024). Characterizing Vascular Wall and Lumen Caliber in Eyes with Diabetic Retinopathy Based on Adaptive Optics Scanning Laser Ophthalmoscopy. https://doi.org/10.3390/diagnostics14182020
  4. Steinberg, R., Meehan, J., Tavrow, D., Maguluri, G., Grimble, J., Primrose, M., & Iftimia, N. (2024). Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.https://doi.org/10.3390/diagnostics14121243
  5. Maguluri, G., Grimble, J., Mujat, M., Park, J., Caron, A., & Iftimia, N. (2022). Fiber-based hand-held RCM-OCT probe for noninvasive assessment of skin lesions and therapy guidance. https://doi.org/10.1002/tbio.202200002

Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea — Ovidius University of Constanța
Mihaela Minea
Affiliation Ovidius University of Constanța
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of Constanța, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Miao Zhou | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Salma Khan | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Salma Khan | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Salma Khan, Loma Linda University, United States

Assoc. Prof. Dr. Salma Khan is a distinguished physician-scientist specializing in gynecologic oncology and thyroid cancer research. With a Ph.D. from Kumamoto University 🇯🇵 and faculty appointments at Loma Linda University 🏥, she excels in translational cancer biology. Her groundbreaking work on health disparities, molecular oncology, and thyroid cancer genomics has earned her multiple honors, including the 2024 AACR Women Cancer Research Award 🌟. She actively contributes to the American Thyroid Association, NIH peer review panels, and serves on several journal editorial boards 📚. Dr. Khan is also a dedicated mentor and advocate for diversity in science and medicine .

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Salma Khan began her academic journey with a Higher Secondary Certificate from Govt. M.M. Ali College, Tangail, Bangladesh (1983–1985). 🎓 She earned her MBBS from Gandhi Medical College, Bhopal, India (1986–1991), followed by an internship at Hamidia Hospital (1991–1992). 🏥 Dr. Khan completed her residency in Obstetrics and Gynecology at IPGMR, Dhaka (1992–1994), and pursued a fellowship at Kumamoto University School of Medicine, Japan (1995–1996). 🌸 Her academic excellence culminated in a Ph.D. in Gynecologic Oncology from Kumamoto University (1996–2000), showcasing her dedication to advancing women’s health.

Awards

Assoc. Prof. Dr. Salma Khan has received numerous accolades throughout her distinguished career. She was honored with the Best Mentor Award by BMANA in 2025 (San Francisco), 2023 (Los Angeles), and 2020 (Dallas). 🌟 In 2024, she received the AACR Women Cancer Research Award and the Best Basic Science Research Award in California. 🎗️ A frequent recipient of Travel Awards from the American Thyroid Association (2016–2023), Dr. Khan also earned top honors at scientific meetings and was a keynote speaker in Japan and Korea (2015). 🌍 Her journey began with prestigious academic scholarships in Bangladesh, India, and Japan.

Research Focus

Assoc. Prof. Dr. Salma Khan focuses her research on cancer biology, with a specialized emphasis on exosomes, survivin biology, and biomarkers for early cancer detection, particularly in prostate and breast cancers. Her groundbreaking studies explore how tumor-derived exosomes contribute to cell signaling, apoptosis inhibition, and metastasis, highlighting survivin as a pivotal player and potential diagnostic marker. Dr. Khan’s work intersects molecular oncology and translational medicine, aiming to bridge lab findings with clinical applications. Her contributions are instrumental in advancing non-invasive diagnostic tools and improving cancer prognosis across diverse populations.

Publication Top Notes

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer

Survivin is released from cancer cells via exosomes

Early diagnostic value of survivin and its alternative splice variants in breast cancer

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential

PTEN promoter is methylated in a proportion of invasive breast cancers

Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro

Differential MicroRNA‐Signatures in Thyroid Cancer SubtypesProteomic profiling of serum-derived exosomes from ethnically diverse prostate cancer patients

Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP)

LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity

The emerging role of exosomes in survivin secretion

Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2 Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Francesco Ceppa | Precision Medicine | Excellence in Research

Published on by Top Pharmaceutical

Francesco Ceppa | Precision Medicine | Excellence in Research

Dr Francesco Ceppa,Università cattolica del sacro cuore,Italy

Dr. Francesco Ceppa 👨‍⚕️Born on May 15, 1994, in Pescara, Italy 🇮🇹, Dr. Francesco Ceppa is a dedicated medical professional specializing in Emergency Medicine at the prestigious A. Gemelli Hospital, Università Cattolica del Sacro Cuore 🏥. A graduate in Medicine and Surgery 🎓 (2020), he has excelled with advanced certifications like Advanced Life Support (ALS) 🩺. Dr. Ceppa gained invaluable experience as a COVID-19 vaccinator and through clinical roles in emergency medicine and abdominal surgery. Fluent in Italian 🇮🇹 and proficient in English 🌍, he combines excellent interpersonal 🤝, organizational 📋, and technical skills 💻 to advance patient care.

Publication Profile

orcid

 Academic Background

Dr. Francesco Ceppa is a dedicated medical professional who graduated from the Università Cattolica del Sacro Cuore with a degree in Medicine and Surgery, earning an impressive score of 101/110 🎓. His strong academic foundation is complemented by an outstanding high school diploma 📚 and proficiency in English at the C1 level 🌍. In line with his commitment to excellence in healthcare, Dr. Ceppa obtained an Advanced Life Support (ALS) certification in 2022 🩺, equipping him to handle critical medical situations with expertise. His achievements highlight his passion for advancing his skills and making a meaningful impact in the field of medicine. 💡✨

Professional Experience

Dr. Ceppa has showcased exceptional expertise through various impactful roles. 💉 During the COVID-19 pandemic, he actively contributed to public health by participating in antigen testing and vaccination campaigns. 🩺 His journey in Emergency Medicine began with a residency at the renowned Agostino Gemelli University Hospital, highlighting his commitment to critical care and acute medical settings. 🚨 Additionally, Dr. Ceppa has been involved in clinical collaborations with key departments, including surgery and translational medicine, fostering interdisciplinary connections that may pave the way for groundbreaking research. 🔬 His dedication exemplifies a blend of hands-on care and forward-thinking innovation. 🌟

Research Contributions

Dr. Francesco Ceppa is a dedicated medical professional with exceptional expertise in emergency medicine, holding an Advanced Life Support (ALS) certification 🩺. Renowned for his technical proficiency, he is rated “excellent” in utilizing medical equipment and computer systems for efficient healthcare delivery 💻. His outstanding teamwork and organizational skills 🤝 ensure seamless collaboration in research and clinical settings. However, his CV lacks explicit mention of peer-reviewed publications, conference presentations, research grants, or independent projects, as well as specific contributions to advancing medical science or methodologies. Strengthening these areas could further highlight his impact and expertise in the medical field. 📚✨

Jose M. Soriano | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jose M. Soriano | Precision Medicine | Best Researcher Award

Prof Jose M. Soriano, University of Valencia, Spain

Prof. José M. Soriano is a Full Professor at the Faculty of Pharmacy, Universitat de València, specializing in food safety, toxicology, and nutrition. He holds a Ph.D. in Food Safety and Toxicology (2001) and degrees in Pharmacy (1996) and Human Nutrition and Dietetics (2018). He has led over 50 national and international projects and published 199 journal articles. With an impressive citation index of 5,263, Prof. Soriano is also Editor-in-Chief of the Spanish Journal of Human Nutrition and Dietetics and has published 50 books. His research focuses on nutraceutics, food safety, and toxicology. 📚🍏🔬

Publication Profile

Google Scholar

Academic Background

Prof. José M. Soriano holds a doctorate in Food Safety and Toxicology, along with degrees in Pharmacy and Human Nutrition. With extensive experience in pharmacy, food science, and nutrition research, he is a Full Professor at Universitat de València. His expertise covers critical areas such as food safety, toxicology, and nutrition, where he contributes to advancing scientific understanding. Prof. Soriano’s work bridges academia and practical application, ensuring a deep impact on public health and safety. 🍏🔬📚

Research and Innovations

Prof. José M. Soriano is a distinguished researcher with extensive expertise in food safety, nutrition, and toxicology. He has led over 50 national and international projects, significantly advancing scientific understanding in these critical areas. With more than 5,200 citations and 199 publications in renowned journals, his work has made a lasting impact. Prof. Soriano’s involvement in over 20 consultancy and industry projects further highlights the practical application of his research. His contributions continue to shape the fields of food safety and toxicology, ensuring better public health and informed industry practices. 📚🔬🌍🥗🧬

Editorial and Collaborative Roles

Prof. José M. Soriano is a renowned expert in human nutrition and dietetics, currently serving as the Editor-in-Chief of the Spanish Journal of Human Nutrition and Dietetics. Through his leadership and extensive collaborations with prestigious institutions across Africa and Asia, he actively contributes to advancing research and education in the field. Prof. Soriano’s dedication to improving global health, particularly through nutrition, has earned him recognition across continents. His work plays a significant role in fostering knowledge exchange and implementing impactful solutions in diverse healthcare settings. 🌍🍏📚💡👨‍⚕️

Professional Recognition

Prof. José M. Soriano is highly esteemed within the scientific community, evident through his memberships in prestigious organizations like the Spanish Academy of Nutrition and Dietetics and the Academy of Pharmacy of the Valencian Community. His recognition in these influential bodies reflects his significant contributions to the fields of nutrition, dietetics, and pharmacy. Through his work, Prof. Soriano has earned respect and credibility, underscoring his dedication to advancing knowledge and practices in these vital areas. His ongoing involvement with these academies is a testament to his ongoing impact and influence. 👨‍⚕️📚🏅

Research Focus

Based on the provided research publications, the individual appears to focus primarily on food safety and toxicology, with a particular interest in mycotoxins and their effects on human health. Their work spans areas like the toxicity, occurrence, and detoxification of mycotoxins such as aflatoxins, zearalenone, and fumonisins. Additionally, they have explored the mechanisms of action of sphingolipids in toxicity, food contamination, and microbiological quality in food products like lettuce and milk. This researcher is also involved in studies on obesity and nutrition, highlighting their expertise in both food toxicology and clinical nutrition. 🧪🍽️🔬🦠

Publication Top Notes

Review on the toxicity, occurrence, metabolism, detoxification, regulations and intake of zearalenone: an oestrogenic mycotoxin

Mechanism of action of sphingolipids and their metabolites in the toxicity of fumonisin B1

Presence of aflatoxin M1 in pasteurized milk from Morocco

Determination of aflatoxins in peanuts by matrix solid-phase dispersion and liquid chromatography

Assessment of the microbiological quality and wash treatments of lettuce served in University restaurants

Incidence of ochratoxin A in rice and dried fruits from Rabat and Salé area, Morocco

Incidence of microbial flora in lettuce, meat and Spanish potato omelette from restaurants